Q2 2025 Thermo Fisher Scientific Inc Earnings Call
Good morning, ladies and gentlemen, and welcome to the thermofisher. Scientific 2025, second quarter conference call.
After the prepared remarks, you have, the opportunity to ask any questions, which you can do. So, by pressing star, followed by the number 1 on your telephone keypad.
Speaker Change: I would like to introduce our moderator for the call Mr. F Isla harder, vice president, investor relations, Mr. Tahara, you may begin the call.
Speaker Change: Good morning, and thank you for joining us on the call. With me today is Mark, Kasper, our chairman president and chief executive officer, and Stephen Williamson, senior vice, president and Chief Financial Officer. Please note, this call is being webcast live and will be archived on the investor section of our website, thermofisher.com under the heading news events and presentations on October 21st 2025.
Speaker Change: A copy of the press release of our. Our second quarter earnings is available in the investor section of our website under the heading financials. So before we begin, let me briefly cover our Safe Harbor statement.
Speaker Change: Various remarks that we may make about the company's future expectations plans and Prospects constitute forward-looking statements for purposes of the Safe Harbor. Provisions under the private Securities. Litigation Reform, Act of 1995
Speaker Change: Actual results May differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussing, the company's most recent annual report on form, 10K.
Speaker Change: And subsequent quarterly report on form, 10 Q which are on file with the SEC and available in the investor section of our website under the heading financials SEC, filings.
Speaker Change: Website under the heading financials. So with that, I'll now turn the call over to mark.
Mark Kasper: Thank you, RAF. Good morning, everyone, and thanks for joining us today for our second quarter call.
Mark Kasper: As you saw in our press release, we delivered excellent operational performance. In the quarter reflecting active management of our company and the strength of our proven growth strategy and PPI business system.
Mark Kasper: Our trusted partner status is more relevant than ever and is resonating strongly with our customers.
This is allowing us to continue to drive market, share gains and highlight our unique ability to enable their success in all Market environments.
Mark Kasper: So, turning to the details of Q2, let me first recap, the financials, our Revenue in the quarter grew 3%, to 10.85 billion. Our adjusted operating income grew 1% to 2.38 billion dollars.
Mark Kasper: Q22 adjusted operating margin was 21.9%.
And adjusted EPS was 5.36 cents per share.
Mark Kasper: These results were ahead of our guidance. During the quarter, our team aggressively mobilized to take the actions to navigate the policy environment and minimize the impact of tariffs for 2025 and Beyond.
Mark Kasper: Stephen will provide some more details on our progress.
Speaker Change: I'll Now cover our performance by End Market.
Speaker Change: In Pharma and biotech. We delivered mid single-digit growth. This quarter representing a nice. Sequential Step Up Performance in the quarter was led by our Bop production and farmer Services businesses as well as our research and safety Market Channel.
Speaker Change: It was also good to realize a sequential improvement in our clinical research business which delivered slightly positive growth in the quarter.
Speaker Change: Current to academic and government revenue declined, mid single digits in the quarter, reflecting some customer hesitancy in a more uncertain environment, resulting in muted demand for equipment and instruments.
Speaker Change: In industrial and applied performance played out as we expected with growth declining in the low single digit store, in the quarter, in Q2, we delivered good growth in our research and safety Market Channel.
Speaker Change: And finally, in Diagnostics and Healthcare Revenue declined in the low single digits during the quarter as we navigated headwinds in China.
Speaker Change: A highlight of the quarter was strong growth in our transplant diagnostic business.
Speaker Change: Wrapping up on the end markets are team manage the current environment, well helping us deliver on our financial commitments for the quarter.
Speaker Change: I'm going to keep my comments a little short of today so I can leave time to discuss a couple topics that seem to be of mine on top of Mind in the investment community.
Speaker Change: So let me give you an update on how we execute our growth strategy in Q2 which drives value creation for our investors.
Speaker Change: As a reminder, our strategy consists of 3 pillars, high impact Innovation or trusted partner status with customers and our unparalleled commercial engines.
As you all have heard me, share before we consistently deliver really outstanding Innovation. We have some great launches this quarter.
We launched several state-of-the-art Solutions at this year's asms conference, highlighted by 2, Next Generation thermal scientific orbit, trap, Mass spectrometers the Astro zoom and the exceeding Pro. As you know, we're an industry leader in the space and these Cutting Edge. Analytical instruments will enable researchers to further Advance Precision medicine and drive significant insights, to help Pioneer new therapies for complex diseases, like Alzheimer's and cancer.
Speaker Change: Customer feedback has been incredibly positive with 1 calling the Astro, Zoom a paradigm shift for proteomic technology and noting that the exceeding Pro provides immediate value to their biotechnology work and will serve as their next Generation platform.
Speaker Change: Also doing the quarter, we launched the thermos. Scientific cryos 5 cry, transmission. Electron microscope, which further. Enhances our leadership in electron microscopy, and empowers researchers to uncover critical biological insights. And to support the development of new Therapeutics,
Speaker Change: Additionally, we expanded our Dino Drive single-use, bioreactor portfolio for Bio production with the first of its kind bench scale system. Helping bio Pharma customers, increase workflow, efficiencies and seamlessly scale up manufacturing of these Therapies.
Speaker Change: Our trusted partner status which we built over many years is another example of why our growth strategy is working and where we're so well positioned for the future. You can clearly see this momentum in our performance with Pharma and biotech.
With the ultimate goal of taking time and cost out of the drug development process.
Speaker Change: During the quarter, it was great to see the tough center for the study of drug development, validate the power and benefit of our unique capabilities and I'm pleased to state that the customer uptake is very strong with clinical research authorizations growing strongly in the quarter.
Speaker Change: Because of the unique relationship, we have with our customers. We are partnering with them to tailor. How we help them navigate and thrive in the current environment for some customers? This means expanding us capacity for drug production.
Speaker Change: And supporting the reassuring efforts for others. It's about accelerating clinical research timelines by aggressively adopting AI into our processes.
Speaker Change: And then there are customers where it's all about, identifying ways to help them Drive productivity.
Speaker Change: Wrapping up my comments on the growth strategy, we're uniquely positioned to win in this environment. Let me provide a few comments on Capital deployment.
Speaker Change: We continue to successfully execute our proven Capital deployment strategy, which is a combination of strategic m&a and returning Capital to our shareholders.
Speaker Change: As you recall in February, we announced that we had entered into a definitive agreement to acquire, sentiments, purification, and filtration business.
Speaker Change: Last month, we amended our agreement to remove Soviets. Drinking water filtration business from the transaction, which allowed us to both accelerate the regulatory clearance process and narrow the scope of the acquisition to the business lines. Most synergistic with thermal Fisher.
Speaker Change: We have received all regulatory clearances and we're on track to close the transaction before year end.
Speaker Change: We're excited to welcome our new colleagues to the company and bring the benefits of Samantha purification and filtration technology to our customers.
Speaker Change: And then shortly after the quarter closed, we announced an expansion of our strategic partnership with sopi to enable additional us drug product, Manufacturing.
Under the agreement, we will acquire syni, sterile finish site in Richfield, New Jersey, and continue to manufacture a portfolio of therapies for seniors.
Speaker Change: We will also invest in expanding production at the site to meet the growing demand for us manufacturing capacity from our Pharma and biotech customers. This is a great example of the power of our trusted partner status and capital deployment strategy at work.
Speaker Change: As always, our PPI business system was a key enabler of our strong execution, in the quarter and drives competitive Advantage for thermal Fisher.
Speaker Change: We're leveraging PPI to adjust our supply chains in the Tariff environment, and to aggressively manage our cost base.
And we continue to further strengthen the PPI business system by incorporating AI to enhance how we serve customers streamline, internal processes and reduce cost.
Speaker Change: Ppi is enabling exec, excellent execution today and will continue to do so in the future.
So, let me now turn to our guidance.
Speaker Change: We're increasing our guidance for the full year on the top and bottom line.
We now expect Revenue in the range of 43.6 billion to 44.2 billion.
Speaker Change: and adjusted EPS in the range of 22.22 to $22.84 per share a 23 cents, increase at the midpoint,
Speaker Change: This reflects continued, active management of the business, Stephen will take you through the details in his remarks.
Speaker Change: Let me now turn to a couple of questions that seem to be top of mind for investors.
Speaker Change: the first is, what is our early thinking on the potential impacts of the US policy focus and tariffs on the near-term growth outlook for thermal Fisher
Speaker Change: And second in that scenario how are we managing the company to create meaningful shareholder value?
Speaker Change: Given our strong conviction of the long-term growth drivers of our industry. We thought it'd be most helpful to you if we zoomed in on the Neo Neo term.
Speaker Change: Say, the 2026 2027 time, frame to focus these questions.
Speaker Change: We believe that a reasonable assumption is that our end markets will gradually build from the lower growth environment that we're currently navigating.
Speaker Change: This would lead to a 2026 and 2027 scenario where we will deliver 3 to 6% organic Revenue growth.
Speaker Change: Today we're currently at the low end of this range and we believe that our growth will accelerate over the next 2 years.
Speaker Change: Given that Topline scenario here is how we're focused on driving shareholder value creation.
Speaker Change: As you've heard me say before our trusted partner status is a meaningful differentiator for us with our customers. They're relying on us to enable their success as they adapt to the environment.
Speaker Change: Second, we're actively managing the company. You see that in our results and the 2025 Financial Outlook
Speaker Change: strong cost management was a focus at the beginning of the year embedded, in our original guidance, and we've meaningfully stepped up the action. As the year has progressed, adding an additional 300 million dollars of cost reduction since the initial guide
Speaker Change: and we will continue that intense focus in 2026 and 2027.
This will result in US delivering strong, adjusted operating income growth of mid to high single digits.
Speaker Change: And when you factor in or disciplined Capital deployment strategy, we have the opportunity to further compound our returns.
Speaker Change: The final point I want to make is that the long-term drivers of the industry remain very compelling. We expect the environment to improve over the next couple of years. And during that time, we'll deliver very strong earnings growth. When I Look To The Future, when this once this near-term scenario plays out, we expect to deliver 7% Plus organic Revenue growth
Speaker Change: So to summarize our key takeaways from the quarter, we delivered. Excellent operational. Performance driven by our proven growth strategy and PPI business system, beating our guidance and raising, our outlook for 2025
Speaker Change: Our trusted partner status and proven ability to enable our customer. Success is a significant competitive advantage.
Speaker Change: We're actively managing the company. In this environment, we're gaining share and driving greater productivity and cost reduction.
Speaker Change: And I remain incredibly confident in the near, and long term outlook for the company. With that, I'll now hand the call over to our CFO Stephen Williamson. Stephen
Stephen Williamson: Thanks Mark, and good morning everyone. I'll take you through an overview of our second quarter results for the total company, then provide color on a 4 business segments and I'll conclude by providing our updated 2025 guidance.
Stephen Williamson: Before I get into the details of our financial performance, let me provide you with a high-level view of how the second quarter played out versus our expectations at the time of the last earnings School.
Stephen Williamson: In Q2 at Team executed really well and we delivered ahead of what we'd assumed in the midpoint of our prior guidance. On both the top and bottom line.
This performance reflects very active management of the company, both to minimize the Tariff and broader policy, impacts and enable the success of our customers.
Stephen Williamson: On the top line, Q2 organic Revenue. Growth was approximately 75 million ahead of what we'd included in the prior. Guidance driven by sales in China, being less impacted by tariffs than we've been had been assumed
Stephen Williamson: In aggregate the rest of the business performed in line with our expectations, which is an excellent outcome, given the macro environment.
Stephen Williamson: Then on the bottom line we delivered 13 cents of adjust. EPS ahead of what was included in the prior guide for Q2 reflecting excellent. Operational execution
8 cents of the beat was from lower impact to terrorists and have been assumed in the prior guide and 5 cents of the beat was from strong cost management enabled by the PPI business system.
Stephen Williamson: So, excellent. Operational performance in Q2.
Stephen Williamson: Let me now provide you with some additional details on the quarter.
Stephen Williamson: Starting with earnings per share in the quarter. Adjusted EPS was 5.36. Gaap EPS in the quarter was $4.28 up 6% from Q2 last year.
Stephen Williamson: On the top line, Q2 reported Revenue, grew 3%. Year-over-year
Stephen Williamson: Revenue growth included, 2%, organic Revenue growth. A slight contribution from Acquisitions and a 1% Tailwind from foreign exchange.
Stephen Williamson: Within our Revenue growth for the quarter, we had a 1% headwind from the runoff of the pandemic related Revenue.
Stephen Williamson: Turning to our organic Revenue performance by geography in Q2 North America and Europe.
Stephen Williamson: Both grew low single digits and asia-pacific declined, low single digits with China, declining High single digits.
Stephen Williamson: With respect to our operational performance, we delivered 2.38 billion dollars of adjusted operating income in the quarter, an increase of 1% year-over-year and adjusted operating margin was 21.9% 40 basis points, lower than Q2 last year and flat sequentially to q1 2025.
in Q2 the year-over-year impact of tariffs and related effects, was a 5% headwind to adjusted operating income dollars and a headwind to report, a margins in the quarter of 140 basis points,
Stephen Williamson: The rest of the business, which drove a 100 base points of margin Improvement in the quarter, demonstrating, our ability to drive strong strong earnings growth in a more muted Topline environment.
Stephen Williamson: We delivered very strong productivity, which enable us to fund strategic Investments to further Advance our industry leadership and offset the impact of unfavorable mix.
Stephen Williamson: Total company adjusted gross margin in the quarter was 41.3%, which is 80 basis points lower than Q2 last year.
Tariffs and related FX reduced, the adjusted growth margins by approximately 100 150 basis points.
Stephen Williamson: This is partially offset by 70 basis points of improvement across the rest of the business.
Stephen Williamson: Moving on to the details of the p&l are just as Sin in. The quarter was 16.2% of Revenue. R&D expense was 352 million in Q2 reflecting at our ongoing investments in high impact innovation.
Stephen Williamson: And R&D as a percent of our manufacturing Revenue was 7.4% in the quarter.
Stephen Williamson: Looking at our results below the line at Q2 net interest, expense was 107 million as expected. The adjusted tax rate in Q2 was 10%.
Stephen Williamson: An average diluted shares with 378 million 5 million lower year-over-year driven by share repurchases, net of options solution.
Stephen Williamson: Turn to free cash flow and the balance sheet year to date. Cash flow from operations was 2.1, billion dollars and free cash flow was 1.5 billion after investing 645 million of net, capital expenditures.
Stephen Williamson: During the quarter, we repay approximately 700 million of senior notes and returned $60 million of capital through dividends.
Stephen Williamson: We entered the quarter with 6.4 billion dollars in cash and short-term Investments and 35.2 billion dollars of total debt.
Stephen Williamson: A leverage ratio, at the end of the quarter was 3.2 times gross debt to adjusted ebitda and 2.7 times on a net debt basis.
Stephen Williamson: And concluding my comments on our total company performance adjusted roic was 11.3%, reflecting the strong Returns on investment that were generating across the company.
Stephen Williamson: Now, I'll provide some color on the performance of our 4 business segments.
In life science Solutions, Q2 reported Revenue in the segment, increased 6% versus the prior year quarter and organic Revenue growth was 4%.
Stephen Williamson: And growth in the segment was led by a bio production business which had another quarter of excellent growth.
Stephen Williamson: Q2 adjusted operating income for life science Solutions. Increased 6% and adjusted operating margin with 36.8% up 10 basis. Points versus the prior year quarter.
Stephen Williamson: During Q2, we delivered, very strong productivity, which was partially upset, by the expected impact of the oil in acquisition, unfavorable mix and strategic Investments.
In the analytical instrument segment, reported Revenue declined 3% and organic growth was 4%, lower versus a year ago quarter.
Stephen Williamson: This was driven by the impact of tariffs and the policy focus of the US Administration which is leading to a more muted demand for equipment and instrumentation.
In this segment Q2 adjusted operating income decreased 26% and adjusted operating margin was 18.8% down 580 basis points versus the year ago quarter.
Stephen Williamson: The majority of the margin change was driven by the impact of tariffs and related FX.
Stephen Williamson: Outside of that impact. Strong productivity was more than offset by lower volumes and strategic Investments.
Stephen Williamson: Turning to Specialty Diagnostics in Q2, reported Revenue grew 2% year-over-year and organic Revenue was flat compared to the year ago quarter in Q2 growth in this segment with led by our transplant Diagnostics business.
Stephen Williamson: Q2 adjusted operating income for specialty. Diagnostics increased, 3% and adjusted operating margin was 27% 30 basis points, higher than Q2 2024.
Stephen Williamson: During the quarter, we delivered good productivity, which was partially offset by unfavorable mix and strategic Investments.
Finding the laboratory products and bioer services, segment reported Revenue, increased 4% and organic Revenue. Grew 3% versus the prior year quarter in Q2 growth. In the segment was led by a farmer Services business and our research and safety Market Channel.
Stephen Williamson: The runner for pandemic related Revenue, had over a 1% impact on the revenue growth in this in this segment in Q2.
Q2 adjusted operating income in the segment. Increased 11% and adjusted operating margin was 13.8%. 90 basis points higher than Q2 2024
Stephen Williamson: In the quarter, we delivered very strong productivity, which is partially upset by unfavorable mix and strategic Investments.
Stephen Williamson: The attorney to guidance is marked outlined. We're increasing at 2025 full year guide to reflect the Q2 beats and that continued active management to the company. Let me provide you with a details
An expected range of 43.6 to 44.2 billion.
Stephen Williamson: Organic Revenue. Growth is still expected to be in the range of 1 to 3%.
Stephen Williamson: We're increasing our outlook for adjusted operating margin in 2025 to a new range of 22.5 to 22.7%.
Stephen Williamson: And we're raising our adjusted EPS, guidance, to a new range of 22.22 to 22.84.
The increase of the midpoint of the guidance range reflects 120 million dollars, higher revenues on the prior guide 30 basis points of improved adjusted operating margin and 23 cents of higher adjusted eps.
Stephen Williamson: This incorporates the Q2 beat as well as an additional 10 cents of adjusted EPS in the second half of the year to reflect additional cost actions. We're taking to continue to actively manage that cost base.
Stephen Williamson: And it's important to note that our organic outlook for the second. Half of the Year remains on track to the prior guidance.
Stephen Williamson: The us-china, Tariff situation has improved significantly versus our prior guidance assumptions.
Stephen Williamson: We reflected the Q2 benefit of that in our revised guidance.
Stephen Williamson: Given the fluidity of the Tariff and trade policy environments. We thought it was appropriate to keep the Tariff impact outlook for the second half. Unchanged at this point.
Stephen Williamson: Should Global tariffs remain as they are today. Will likely have upsides to the new guidance.
Stephen Williamson: We're actively managing the company to appropriately navigate the macro environment. A growth strategy is enabling customer success and driving share gain and we're using the PPI business system to effectively address tariffs and aggressively manage our cost base.
Stephen Williamson: Our initial guide for the year included, very strong, earnings growth enabled by aggressive cost management. And since then, we've added an additional 300 million dollars of cost actions for 2025.
Stephen Williamson: For PPI, we're constantly finding ways to be more productive.
And to leverage the scale of the company.
This includes increasing the utilization of our shared services and our functional centers of excellence, PPI drives strong strong earnings growth and also creates room in the p&l to continue to invest for the future.
Stephen Williamson: And now move on to an update of some of the modeling elements for the full year.
Stephen Williamson: Ethics rates continue to fluctuate in the quarter driven by changes in tariffs and trade policy.
Stephen Williamson: In Q2 the year-over-year FX impact on Revenue. Improved 600 million 6360 million dollars versus our pride guide, but the adjusted EPS impact worsened, by 8 cents, largely due to 1 time transactional effects caused by intra core to volatility in rates
Stephen Williamson: Which if FX rates stay as they are today will not reoccur in 2026.
So for the full year, we now expect FX to be a year-over-year Tailwind to revenue of $10 million and a headwind to adjusted operating income and adjusted DPS of $80, million and 27 cents respectively.
Stephen Williamson: Below the line. We now expect net interest expense to be between 360 and 370 million in 2025.
Stephen Williamson: And we continue to expect an adjusted tax rate of 10.5% for the full year.
Stephen Williamson: We continue to expect between 1.4 and 1.7 billion dollars of net, capital expenditures in 2025 and free cash flow in the range of 7 to 7.4 billion dollars for the year.
Stephen Williamson: In terms of capital employment, we're assuming 2 billion dollars a share BuyBacks, which were already completed in January.
Stephen Williamson: We continue to estimate the full year, average diluted share count will be between 378 and 379 million shares.
Stephen Williamson: And we'll return approximately 600 million dollars of capital to shareholders this year through dividends.
Stephen Williamson: Our guidance does not include any future Acquisitions or diversities. So it does not include any impact from the pending Acquisitions of sventom purification and filtration business and the sterile finish site from Sumi,
in terms of phasing for Q3,
we expect organic growth in Q3 to be about a point higher than Q2 and adjusted EPS to be approximately 10 to 15 cents higher than Q2.
And then, finally 1 of the touch on the financial scenario for the next couple of years that Mark outlined earlier.
Stephen Williamson: so when managing the company under the assumption that will deliver between 3 and 6%, organic Revenue growth in that period, that includes a continuation of the strong share, gains that we've been delivering
Stephen Williamson: In that Top Line environment using the proven levers of the PPI business system, we expect to generate approximately 50 to 70 basis points of adjusted operating margin expansion.
And mid to high single digit, adjusted operating income growth.
Stephen Williamson: We have a number of exciting opportunities to supplement, this organic performance, with effective Capital deployment.
Stephen Williamson: Level of growth and should this occur will be in a great position throughout to drive even better performance.
Stephen Williamson: So to conclude, we continue to actively manage the company and are effectively navigating the macro environments.
Stephen Williamson: Our customers are working on incredibly relevant science to address huge unmet needs in the world, and we're uniquely positioned to enable their success.
With that, I'll turn the call back over to mark.
Mark Kasper: Thanks, Stephen.
Before we open the call for questions, I'd like to take a moment to share an update about our leadership team that involves great news for 2. People whom I hold in very high regard and work very closely with
Mark Kasper: first, Stephen Williamson, our Chief Financial Officer has decided to retire next year at the end of March.
Mark Kasper: This was thoughtfully planned on his part and I know that he and his wife, Jane are very excited for his upcoming retirement.
Mark Kasper: Steven has had an extraordinary impact on thermal Fisher Scientific.
Since taking on the CFO role in 2015, he has been instrumental in driving, our company's financial performance and strategic growth. And he has built deep relationships with our investors and colleagues.
Speaker Change: I've had the privilege of working closely with Stephen, for nearly 25 years.
Mark Kasper: He's been a true partner.
Mark Kasper: Insightful, thoughtful and always focused on the long-term success of our company.
Mark Kasper: I deeply appreciate his guidance, his unwavering commitment, his steady leadership and the impact has he that he has had on our success? Our success?
Speaker Change: While certainly missing him, the entire company is incredibly grateful for his contributions.
Speaker Change: And we wish him the very best and is well deserved upcoming retirement.
Speaker Change: next, I'm very pleased to share that as part of a long plan, transition, Jim Mayer currently or vice president of financial operations, and member of the company leadership, team will become our Chief Financial Officer effective, March 1st 2026,
Speaker Change: Jim, it is a is an accomplished Finance leader with deep company, knowledge and a strong track record across our organization.
Speaker Change: He joined thermal Fisher in 2009 and has held senior Finance roles across several of our major businesses. And in his current role, he leads the finance support for all of our operating businesses over the past few years, I've had the opportunity to work closely with Jim. He's exceptionally qualified to take on this role and will continue to drive film officials long term growth and outstanding.
Speaker Change: Financial performance.
Speaker Change: Steen and Jim will work together closely over the coming months to ensure a seamless handoff
Speaker Change: And I look forward to continuing to partner with them during this transition.
With that. I will turn the call over to RAF for questions. Thanks Mark. Operator, we're ready for the Q&A portion of the call.
Speaker Change: Thank you. We will now begin the question and answer session.
Speaker Change: If you would like to ask a question today, please do so. Now by pressing star, followed by the number 1 on your telephone keypad.
Speaker Change: In order to allow everyone in the queue an opportunity to address the Thermo Fisher management team. Please limit your time on the call to 1 question and only 1 follow-up. If you have additional questions, please return to the queue
Speaker Change: Our first question today comes from Michael risking with Bank of America.
Speaker Change: Please go ahead.
Michael Risking: Great. Um, thanks for taking the question and um, congrats Stephen on the retirement and uh, you guys certainly give us plenty to talk about in this in this call. Um Mark, maybe I'll start with the
Speaker Change: Maybe I'll start with a high level 1. Um, you know, would you talk about in terms of the, the new outlook? Um, I think the 7% Plus in the long term, um, sounds like that's the new long-term Outlook with the lrp, um, in the past you've certified talked about, you know, here's what the Market's going to grow. Here's thermal taking care of that uh due to PPI and trusted partner status. Um,
Speaker Change: Could you sort of break that 7% plus down a little bit? Give us a little bit more clarity on that. And then, um, sort of part of that, you know, you talked about the strong conviction and the long-term drivers of the industry. Um, and and sort of how do you arrive at that number? Um, given everything that's happened in the first half. 25, the answer, do we, we still see in the market, what gives you the conviction at 7 plus is the is the right number going forward for the long term.
Mike: Yeah, Mike, thanks for the question. Um,
Speaker Change: so,
Speaker Change: Growth outlook for us. You know what are all the policy impacts Etc. I suppose all in the in the background and
Speaker Change: what we wanted to make sure that all of our investors understood is that we're not waiting for anything to happen, right? We're going to actively manage the business and deliver very strong earnings growth. Um, we've been doing that since the second half of 2024 certainly was embedded in our guidance and as as we've highlighted in our remarks, we've been stepping that up to be able to deliver you know, a strong view on the bottom line.
When I think about the scenario that we're in, what we're really assuming in the 3 to 6%, is that today, we're at the 3% level already. And that, as you get the absence of some of the negatives, meaning that academics not going to keep declining year-over-year over year, but it will stabilize. Even if it returns to zero, you actually get higher and higher in that range. So, it's just working through. And I, and the same thing is true, in clinical research. When I look at authorizations momentum this year, it's a flat this year and aggregate that starts to pick up. So without major changes, um, you're in that range over the next couple of years. Right? And, and, you know, so that's the first aspect of it. I'm sure there'll be other um, analysts of questions about that but then we take to the longer term. And you think about the fundamental drivers um of the industry.
There's a huge need for um, improved Healthcare around the world. The scientific breakthroughs are incredible, when I talked to our biotech and pharmaceutical customer Executives, they're incredibly, excited about what's in their pipelines and the huge unmet needs that they're going after.
Speaker Change: and to be able to say, in the longer term,
Speaker Change: Um, that we're going to be, you know, 7% plus, um, feels very reasonable to us and, you know, we're we believe in our conviction, around our share, gain of that 2 to 3 points, right? And so you can you can kind of back into that. Would say we're getting to the 4% type market growth. Feels very reasonable in the longer term but um
Speaker Change: I'm really focused on the short term right now and delivering just great, you know, experience for our customer share game and, and great operating income. So hopefully that's, uh, growth. So hope this helps helpful. Thank you, Mike.
Speaker Change: Okay, great. And then, um, Stephen 1 for you then, um, talk about the, the margin expansion. That's a couple of years, I think you said 50 to 70 bits of op amp per year. Um, that that's pretty impressive. Given the subdued environment, you've already delivered or you're planning to deliver a good amount of March expansion this year. Um, again, in an uncertain Market, can you talk about the levers, you have there? Um, you know, how much of it is, is PPI versus, um, uh, some of the synergies from the business you brought on, or any
Speaker Change: Particular. It's like when we were pulling the lever, more could just talk about the drivers of that margin gains. Thanks.
Yes. So so Mike and actually just 1 Clarion on on Mark's comment that we're talking about clinical research and you said that um businesses is flat this year and expected to increase going forward. That was an authorization. That's organic Revenue growth and authorizations were very strong in the quarter and as they were last quarter as the businesses in is in very good shape. So, when I think about the 50 to 70 basis points of margin expansion, it's about um, using the same. The same tools in the in the toolbox and from PPI businesses and and we keep we keep in improving the tools in there and you know, we've added AI capabilities in and and as we think about how we manage the company. So um, it's it's really about how do we, where do we spend the organization and energy to to, to use the right levers? And we're not having to invent new things and figure this out. This is all about the, the same levels that we have. And, um, you know what, teams activated in that this year. And I think about what we delivered in, in Q2 we've got, you know, obviously a significant reported margin headwind from the impact of tariffs and FX and, and then underlying the business is delivering 100 basis, points of margin expansion.
Speaker Change: That's demonstrating um, how strong that that growth is in earnings. And I think about that organic viewpoint on earnings growth in the quarter, that was about 6%, so, um, very strong performance, um, in a more muted Topline environment. So that we, we know the right levels and, um, we're confident in the ability to deliver on that. And with that, with that back to you period,
Speaker Change: Thanks Mike.
Speaker Change: Thank you. Our next question, comes from Dan eras with stifel, please go ahead.
Hey, good morning guys. Thank you Mark. Maybe on biofarma. It seems like there's a range of things that are going on right now when it comes to just the investment approaches for these companies, you kind of touched on it. But can you just maybe expand on
Speaker Change: Text segment from the equation where I understand. It's kind of just about how much money you have left in the bank.
Speaker Change: I'm curious, whether there are factors or characteristics, that are emerging, that sort of divide those that are pulling back in response to the macro versus those that are pushing forward. And in some cases, investing more as a pipeline as a geography, is it something else?
Speaker Change: Yeah, thanks for the question.
Speaker Change: So when I think about farm and biotech you know or missing single digit growth, you know we saw broad strength actually across all aspects of the business and um that was a nice sequential step up and actually the best we've seen in 9 quarts. I so I feel very good about that. Um bio production was excellent. Um team did a really good job, strong growth, continuing the trends. We saw in q1, great bookings, growth farmer Services is very strong. Growth makes sense. Right? You know, we've talked about the importance of our Cerro full finish capabilities to do work. We do for, you know, the clinical trial Supply and those things and former Services, you know, excellent demand there, um, research and safety Market Channel continues to do. Well, that's a reflection of sort of the what's going on in the research Labs at biotech and Pharma. And that was a strong performer. And as Stephen and I both have said,
Speaker Change: You know, we turned to Positive Growth while only slightly uh in the quarter for clinical research. It's actually performing as we expected authorization for very, very strong. So those things go really well and um,
Speaker Change: When I think about the conversations with our customers and they may actually be quite surprising to our investors. And whether this is small biotech, I saw a lot of them at the bio conference um that was here in Boston in June large Pharma. Um some of those companies that have grown super well. Are those companies? That might be entering a challenge, the tone is incredibly positive. And so, why is that the case? Um,
I think that they have plans on how to navigate this, you know, the environment.
Speaker Change: I think that as they talk about their pipelines, they feel very good about what's going on in their own pipelines. The understanding of Science and sort of what that boats for the future and there's for the larger companies, there's a real confidence that they can work with governments in this environment and navigate it effectively. So, um, we actually see it as a lean in environment for farm and biotech and they're leaning on us to make that a reality. So um, we're excited about it and you know, it's, you know, it's to be a real driver of our Outlook and, and our current performance
Okay, that's helpful and good to hear. Um Stephen congrats uh on my end as well, looking forward to hearing where that handicap goes from here. How should we be thinking about the analytical instrument business in the back half?
Speaker Change: Obviously, it's tough out there from a capex decision standpoint down for this quarter. You have a similar compax quarter.
Speaker Change: But then you come up against a really strong 4q from last year. So you know, I I know you don't try to get too specific at the segment level, but just given the moving Parts on the hardware side.
Speaker Change: It would be helpful to know how you see growth there in the back half.
Do you think you can finish 2025 with analytical instrumentation being up? Thanks a bunch.
Yes, this is Dan. Thanks for the conversation. So um, when I think about anal,
Speaker Change: Months. Um, we got decent, bookings performance as well. Um, 1 thing, we think about a positive book to bill, um, it it is most impacted by the the Mita conditions in academic and government and, and the economy in China. So there's a kind of, some, some factors that to, to wrap into that. And, um, it seems to focus on executing and making sure that we're, we're getting share. And we're getting the, the most impact from the, the great Innovation, that we've been doing across this segment from a number of years and the new product launches at Mark talked about a continuation of that. So, um, the team is well, positioned and it will navigate the, the, the situation. And then, um, as I said, in my guidance, I I continue the assumptions that I had for tariff impact.
Speaker Change: In the second half of the Year and that that that was a largely passed pessimistic view on um demand in China. And should that not be the case that will be that will be helpful in terms of the demand and the second half of the year, we'll see how that plays out.
Speaker Change: Great. Thanks. Dan.
Speaker Change: Thank you. Our next question comes from. Jack Meehan with nephron research.
Speaker Change: Please go ahead.
Good morning and Stephen. Congratulations. And Jim looking forward to working together.
Speaker Change: Um, conversely, I'm just curious like in 2 Q is, did you see any evidence customers could have been pausing? Purchasing at all? Just the idea being like, if you're going to buy equipment, you got to know where to send it wanted to test out that theory on you.
Jack: Yeah. So um, Jack. Thanks. Um,
Speaker Change: There's a heightened level of interest um and expanding us manufacturing capacity. Um you see that in the large farmer announcements even see it in our announcement last quarter, about expanding our domestic production because leveraging our cdmo capabilities is a very economically effective way as a pharmaceutical customer to reshore capacity and that really is a lot around the Sophie transaction. Um, when I think about does that cause any pause not really actually by our Productions doing really well. Um, and, you know, it takes, you know, multiple years to bring these facilities online. So, you know, it's a 1-time added Tailwind at some point in the future, um, as facilities are opened or expanded. So, um, and then it normalizes, right? Because you don't need to, you know, you don't keep buying more and more equipment, you just, you know, expand your capacity at at your new site. So I think does it tell when that comes up over the next
Speaker Change: Last couple of years, the way I would think about it but I'm not seeing any customers pausing at all in in BIO production so it's been very positive.
Awesome. Okay. And then wanted to flip over to analytical instruments, um, just the organic growth, um, decline this quarter when you talk about some of the policy pressure. Was this all academic, or did you see any of that bleed into Pharma biotech or elsewhere? Um, could you just talk about that a little bit more?
Speaker Change: oh yeah, so so Jack, you know, when I think about um,
Speaker Change: the analytical instruments business, you know, obviously, um, the business performed, um,
Speaker Change: in line, you know, with what we were, you know, expecting given the, um, academic and government environment and the Tariff environment, um,
Speaker Change: We actually, you know, I think actually gained share once again even in this environment. And you know, why is that the case our Innovation is unbelievable, right? If I think about and I've said this many times for many years, which is if you bring out super relevant products, it doesn't matter what the funding environment is customers, find money. If I think about the order book on Astro, Zoom that we launched in June, it's phenomenal right. In terms of customer interest. I mean, it's super cool, right? And none of them are talking about, you know, the funding environment. They're like, wow, this is going to be breakthrough in terms of my research, right? So so so when I think about, you know, the environment, um, you know until there's more visibility if you will to the how the budget
Speaker Change: Play out. You know, I would expect that demand will continue to be muted from academic and government to this customer base. That's why it's embedded in our guidance. Um, it's you know, very much in line with what we said before in terms of nothing's changed and the China headwinds are favorable um to what we had said back in April. So um you know it'll take a bit of time until you get more stability in the sun market but we're well positioned to gain share and, and do a good job serving our customers.
Speaker Change: Thanks sir.
Speaker Change: Thank you. Our next question comes from Rachel varten stall. With JP Morgan. Please go ahead.
Speaker Change: Great. Good morning. And thank you for taking the questions. Stephen, congrats on the long career. Jen looking forward to working with you as well. So I wanted to follow up on my question, regarding those midterm, Targets in 2026 and 2027. It seems like investors are really most concerned about 3, key and markets, for thermal the Pharma and Market given mfn. And some of the tour of concerns academic and government given the funding Dynamic under the new Administration, and then China. So can you walk us through? How are you thinking about those 3 and markets? As we look to the 3 to 6% framework over the next few years and could you rank order for us? Which ones of those do you think are most realistic in terms of being pressured, or being fully resolved, as we come out of this 2026 2027 time frame,
Speaker Change: So Rachel when I think about um the framing right, there's nothing super scientific about it being exactly 2 years. But we wanted to say is that, you know, it's a relatively short-term period. It's the environment that we're in now.
Speaker Change: And what are we seeing? And how do we believe it's a progress? Um, and when you go through, you know, effectively our assumption is that in this period of time, over the next couple of years,
Speaker Change: Write a decline mid single digits um, in the, you know, in the quarter um at some and and that's what we're assuming, you know, we're assuming the headwind for a while, but what happens is the budgets, get set? They don't keep declining. So that eventually in this period, will normalize, if you're not expecting a big funding environment to flatten out, right? So that is the absence of that headwind. You know, effectively happens in this period and farm and biotech actually just based on the momentum in the authorization of clinical research, you know, is going to improve certainly. And that's been our all along. We said 26 is a year of improving growth relative to 25. And most of the industry has said that. And if I look at another large industry participant, they saw very similar Trends. So we did, which is, you know, authorizations activity was good, um, you seeing some level of growth and so, that's the the second driver when I think about China.
Speaker Change: Um, you know it's a headwind right now. Um, we expect that it, the economy continues to be challenged that continues to have some headwinds because of the Tariff environment.
Speaker Change: Our expectation is that over this period. Um, it will flatten out, it doesn't mean it won't be better at some point but right now in the quarter for us, it was, you know, High single digit decline. Um, it'll take some quarters to work through that, but getting back to, sort of a stable at a minimum, um, gets you into that environment. So, as Stephen said, there are clearly scenarios that are better than that. And I'm not smart enough to call exactly how each of these things play out. But I think from our experience to say that we're operating in this 3 to 6% environment, now doesn't take much of a change and sort of what we're seeing to make that a reality. And then whenever that exact quarter is that you're exiting that period. The growth drivers here are very strong and that's why we said the 7% plus seems to make sense to us.
Speaker Change: Thanks, that's helpful. Then I just wanted to dig into the academic and government funding a little bit more and follow up on your answer to Jack's question. So you noted that customers are still finding budgets for your products, which is great to hear. But can you spend a minute talking about? What are you hearing from customers and your consultants in DC regarding the funding outlook for NIH this year?
Speaker Change: yeah, so when I think about what's going on in academic and government, um,
Speaker Change: You know.
Speaker Change: A couple things 1 is personally, I've been quite active, right? In terms of with um, our government and you know, in the dialogue, certainly in Congress as well. Um, you know, there remains a high level of bipartisan support um, for academic and government funding in the Life Sciences. Um, and there's a very clear understanding of the importance of the life sciences um for the health of the US economy and the US is standing in the world. So you know, my belief that you know, you will get to an environment that is meaningfully better than what people are assuming right now, seems you know seems quite reasonable and you know, it's hard to know exactly what that is but I don't think something in the flattish type, you know, flat to, you know, funding environment wouldn't be, you know, out of out of the question. It might be down a little bit but I don't think it's going to be that significant ultimate.
Speaker Change: But we'll see. Um, customers are cautious, right? And they have the dynamic that they have to spend some of the budgets that they have, and they're ALS planning for what the next year is. So you're going to have some heightened caution until the budget environment is, you know, sorted out for 2026. And we reflected that in our guidance, right? We're expecting that us academic and government, um, will be soft in the second half of the Year. Nothing has changed in our view of that or in terms of the impact.
Speaker Change: And um, we'll see how that plays out.
Speaker Change: Thank you.
Speaker Change: Thank you. Our next question.
Speaker Change: Tao Peterson with Jeffrey's. Please go ahead.
Hey thanks. Um, I want to maybe just probe back into Pharma services for a minute and I appreciate, you know, the Colorado, strong bookings and and PPD, you know, on track to get back to Flat for this year. I guess, Mark, as we think ahead, the next year, is there any reason that you know, the cro business isn't back to more normalized? You know, call it high single digit growth and I guess. Yeah. Has anything changed about the longer term outlook on, on, on that side?
Speaker Change: Just periods of incredible growth in clinical research that this was a year of, you know, tough comparison which was well earned, a tough comparison. Um, and that authorizations momentum. That we start saw starting to pick up in the second half of last year would drive the business back to growth. And we're not assuming that right now that there's immediately the high single digit, but a returns to growth and then builds from there, you know, long term when I think about this business,
Speaker Change: Um, this is a high single digit growth business because more work is actually happening in biotech than Pharma ultimately, in terms of where Innovation is and biotech is 100% dependent on Partners to do that work. And um, so you know, the Tailwind here are very, you know, very strong. And we are incredibly well positioned with that, customer base. And so, you know, long term. I feel very good about the growth drivers of a clinical research and, you know, nice to return to Positive Growth. This quarter, nice to get great authorizations growth and setting up for, you know, the continued momentum that we would expect in the second half of the year.
Speaker Change: Okay, and then just follow up.
Speaker Change: Theme on the CD.
You know, the synopsis deal is an interesting 1. I think you've always said asset transfers from Pharma, are some of the better deals you do? Can you maybe talk about the opportunity set their, uh, how you feel about current capacity and feel finish today? And then, you know, maybe just touch on traction with accelerator. How many customers do you have today and and how is that going?
Speaker Change: yeah, so Tau in terms of accelerated drug development, incredibly um, you know, being adopted incredibly across the industry and
Speaker Change: You know, you you see that in the pharmaceutical growth? You see that in the authorizations momentum?
Speaker Change: And the tough study is a nice study to get a third party's view on it. But what's more important is what our customers actually buying and they they're super excited by it because
Speaker Change: They partner with us.
Speaker Change: And now we're really in the how are they operating? And how do we make their drug development process? More time effective and more cost-effective so that they can get their important work to the market. And so that's driving, really, excellent. Momentum, you know, in terms of the Starfall finish and um, the work there, um,
Speaker Change: It's adding a third site um to our us footprint. Um and when we really like acquiring, um, you know, capacity versus a green field because it's a much more cost-effective way of doing it. You have trained operators, you have equipment, that's not 100% utilized and then we're going to expand on that footprint. So it's great news for the team in New Jersey because they'll be working on even more exciting molecules and um, and we'll be able to, you know, you know, meet the demand which is very strong with the increased capacity.
Speaker Change: Policy that we have in New Jersey so it's a really nice acquisition and, uh, we look forward to getting that 1 closed um, before the year ends as well.
Tigo: Thank you, Tigo.
Speaker Change: We have time for 1 more question.
Speaker Change: Thank you. Our final question today comes from the line of Dan Brennan with CD Cohen.
Dan. Please go ahead.
Dan Brennan: Great. Thank you. Uh, thanks for the questions. Uh, Stephen, I like other. Congratulations. And Jim look forward to working with you.
Speaker Change: Maybe just 1 Mark to start just on the 7% plus long-term growth. Uh, I think you said the 4% underpinning of market growth feels good to you.
Speaker Change: I would certainly agree very doable but the last 3 years have been so tough. So maybe a 2-part just with Farm as your biggest customer, just wondering what type of maybe Pharma R&D growth or other kind of factors you would kind of, uh, be using in order to support that 4% growth. If, if, if R&D is a good factor. And I know you talked about the 2 to 3 points of share gains, where do you feel best across your business for those gains?
Yeah. So
when I think about, um,
Speaker Change: A very long-term perspective, um, of serving farm and biotech. Um, and I think about the unique capabilities that we bring
Speaker Change: um,
Speaker Change: We're very well positioned to continue to drive, very strong, share serving that customer base.
And we are involved in all of what drives that industry, right? We Supply their research Labs, we Supply their quality control labs.
Speaker Change: We design their clinical trials, we run their clinical trials.
Speaker Change: We package and distribute their experimental medicines.
Speaker Change: Partner status, that positions us very well.
Speaker Change: I get lots of questions over the year about. What's the aggregate R&D budget or these different things is interesting. It's not actually something that is a major driver, but rather it's that holistic supporting the industry, um, that we have. So I feel very good about our ability to get very strong growth.
Speaker Change: Coming out of our largest, um, End Market and that will drive our long-term growth going forward.
Speaker Change: And then maybe just 1 follow up just on the year. Um, I know you had baked in or Stephen and Market baked in the 400 million
Dan Brennan: Dollar headwind for China. And I, I think there was a 200 million vaccine headwind and Stephen you talked about how that China reversal I think helped the organic growth upside in the quarter so just can you just walk through a little bit? How much of China that 400 million came back in Q2? What's the last and any benefit from the vaccine headwind or is that still contemplated as a drag? Thank you.
Speaker Change: Yep. Yeah, so so, so Dan. Um, so, when I think about the the Tariff dynamic in China, we'd assumed it would be a significant sensation of trade. So, um, we saw that early on in Q2 and that was an impact and, and roughly half of the impact didn't happen in Q2. So, I think these up and that's, that's for the 75 million dollar kind of beat on the top line. That was, you can think about that as a kind of the scale of the benefit in Q2, um, and yeah. So, so we we, we, we have an assumption that things. Uh, basically stay the same as as they were in Q2.
Speaker Change: um, things will get will improve from the guy we've given you, um, at
Speaker Change: At the end of the day, it's probably about a 25% a quarter um cushion that we have against potential other tariff things that could come up. So things, that's an appropriate at this time, not to change the guidance for that and we'll see how the the Tariff environment changes over the next. Um, several quarters.
Speaker Change: Thanks tan, and so let me wrap up here.
Dan Brennan: Um, thanks everyone for joining us on the call today.
Dan Brennan: You know, we're in a strong position as we enter the second half of the Year, we're actively managing the company.
Speaker Change: Continued deliver differentiated performance. Create shareholder value, build an even brighter future for our company. Um, I very much will cherish the upcoming 9 months with Stephen and I look forward to working with Jim on the transition as well. And we all look forward to updating you on our third quarter results in October. And as always, thank you, um, for your support of formal official scientific, thanks everyone.
Speaker Change: And you may now disconnect your line.